Sanofi has secured European approval for a next-generation rabies vaccine, giving the bloc a modernised tool against one of the world’s oldest and deadliest infections. On 19 November, the French pharmaceutical company announced that the European Commission cleared VaxRabeo for use in people of all ages, both to protect those at risk before any exposure and to treat people after a potential bite. It is the first-ever marketing approval for the vaccine, following a positive opinion from the European Medicines Agency’s human medicines committee in September.
Why Rabies Still Matters
Rabies may feel like a disease of the past in much of Europe, but globally it remains a serious threat. The viral infection is present in around 150 countries and kills an estimated 59,000 people a year, according to the World Health Organization. It is almost always spread through the saliva of infected animals, most often via dog bites, and attacks the central nervous system.
What makes rabies so feared is its grim arithmetic: once symptoms appear, it is virtually always fatal. There is no treatment. Yet it is also entirely preventable with timely vaccination, which is why roughly 29 million people receive post-exposure jabs every year. Children are especially vulnerable and around 40% of those bitten by animals suspected of carrying rabies are under 15.
What’s New About VaxRabeo
VaxRabeo is not a radical departure but a careful upgrade. It uses the same viral strain as Sanofi’s long-established vaccines, Verorab and Imovax Rabies, which have been in use for more than five decades, but it is made with modern Vero-cell technology, involving a method of growing the virus in a well-characterised line of cultured cells rather than older production systems.
The practical improvements are the point. The vaccine has been formulated to reduce the risk of allergic reactions, and it is more heat-stable than Sanofi’s current rabies vaccines, with a shelf life of five years. It can hold up at temperatures of up to 27°C for 96 hours before being reconstituted. That thermostability is far from a technicality: rabies hits hardest in parts of Asia and Africa where keeping vaccines cold along the supply chain is a constant challenge, and a jab that tolerates warmth is a jab more likely to reach the people who need it.
How It Performed in Trials
The approval rests on a clinical programme that pitted VaxRabeo directly against Sanofi’s existing vaccines across all age groups and the various dosing schedules the WHO recommends. In pre-exposure use, the new vaccine produced protective antibody levels comparable to the older products in both adults and children. In post-exposure use (after an actual bite) every participant given the vaccine into the muscle reached protective antibody levels, whether or not they also received rabies immunoglobulin, the antibody preparation used alongside vaccination in the most urgent cases.
Booster doses given one to three years later prompted a strong immune response, suggesting lasting protection. On safety, the vaccine behaved much like its predecessors, with no significant concerns flagged.
VaxRabeo also offers flexibility in how it is given, including the WHO’s streamlined two-dose pre-exposure course and a four-dose course for unvaccinated people needing treatment after exposure.
Who Stands to Benefit
The approval matters for two groups. The first is people at occupational or travel risk, including vets, lab workers, and travellers heading to regions where rabies is endemic, where the WHO estimates a traveller faces a potential exposure in roughly 0.4% of cases for each month of their stay. The second, and larger, is the global effort to stamp out human rabies deaths, where a more robust, heat-tolerant vaccine could make a tangible difference.
Thomas Triomphe, Sanofi’s head of vaccines, called the approval a proud milestone built on five decades of work in the field. The company frames VaxRabeo as bringing its rabies protection up to date for modern healthcare systems. For a disease that remains 100% fatal yet 100% preventable, a better vaccine is a quietly significant step.
Sanofi (2026). Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages. 19 November 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-11-19-06-00-00-3406292
European Medicines Agency — VaxRabeo (summary of CHMP opinion, 17 September 2026): https://www.ema.europa.eu/en/medicines/human/EPAR/vaxrabeo